Fate Therapeutics - FATE Stock Forecast, Price & News

22 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last year. There are currently 2 sell ratings, 15 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" FATE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FATE, but not buy additional shares or sell existing shares.
View FATE analyst ratings or view top-rated stocks.

22 Wall Street analysts have issued 12-month target prices for Fate Therapeutics' shares. Their FATE share price forecasts range from $6.00 to $65.00. On average, they anticipate the company's stock price to reach $19.44 in the next year. This suggests a possible upside of 266.7% from the stock's current price.
View analysts price targets for FATE or view top-rated stocks among Wall Street analysts.

Fate Therapeutics' stock was trading at $10.09 on January 1st, 2023. Since then, FATE shares have decreased by 47.5% and is now trading at $5.30.
View the best growth stocks for 2023 here.

Fate Therapeutics saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 21,580,000 shares, an increase of 15.6% from the February 28th total of 18,660,000 shares. Based on an average trading volume of 4,010,000 shares, the days-to-cover ratio is currently 5.4 days. Approximately 23.6% of the company's stock are sold short.
View Fate Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our FATE earnings forecast.

Fate Therapeutics, Inc. (NASDAQ:FATE) posted its quarterly earnings results on Tuesday, February, 28th. The biopharmaceutical company reported ($0.58) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.86) by $0.28. The biopharmaceutical company had revenue of $44.36 million for the quarter, compared to analyst estimates of $18.41 million. Fate Therapeutics had a negative net margin of 292.55% and a negative trailing twelve-month return on equity of 50.86%. The firm's revenue was up 159.9% compared to the same quarter last year. During the same period last year, the firm posted ($0.72) EPS.

ETFs with the largest weight of Fate Therapeutics (NASDAQ:FATE) stock in their portfolio include Loncar Cancer Immunotherapy ETF (CNCR), iShares Genomics Immunology and Healthcare ETF (IDNA), SPDR S&P Biotech ETF (XBI), AdvisorShares Alpha DNA Equity Sentiment ETF (SENT), Direxion Daily S&P Biotech Bull 3x Shares (LABU), AI Powered Equity ETF (AIEQ), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and ROBO Global Healthcare Technology and Innovation ETF (HTEC).

2 employees have rated Fate Therapeutics Chief Executive Officer Scott Wolchko on Glassdoor.com. Scott Wolchko has an approval rating of 100% among the company's employees. This puts Scott Wolchko in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Fate Therapeutics investors own include Cara Therapeutics (CARA), CRISPR Therapeutics (CRSP), Juno Therapeutics (JUNO), NVIDIA (NVDA), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Sorrento Therapeutics (SRNE) and Gilead Sciences (GILD).

Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."

Fate Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (4.34%), Millennium Management LLC (2.95%), Price T Rowe Associates Inc. MD (2.74%), Renaissance Technologies LLC (1.86%), Morgan Stanley (1.79%) and Geode Capital Management LLC (1.61%). Insiders that own company stock include Bahram Valamehr, Cindy Tahl, Daniel D Shoemaker, Edward J Dulac III, J Scott Wolchko, John Mendlein, Louis T Petrillo, Mark Plavsic, Redmile Group, Llc, Shefali Agarwal and Yu-Waye Chu.
View institutional ownership trends.

Shares of FATE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of FATE stock can currently be purchased for approximately $5.30.

Fate Therapeutics (NASDAQ:FATE) has a market capitalization of $520.25 million and generates $96.30 million in revenue each year. The biopharmaceutical company earns $-281,720,000.00 in net income (profit) each year or ($2.91) on an earnings per share basis.

The company employs 449 workers across the globe.

Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.fatetherapeutics.com. The biopharmaceutical company can be reached via phone at (858) 875-1800 or via email at christina@sternir.com.